Kyverna Therapeutics (KYTX)

• Market cap: $537M
• 1 day: 0.8%
• 5 days: -4.62%
• 1 month: 1.14%
• 3 months: 6.48%
• 6 months: 28.92%
• Year to date: 1.14%
• 1 year: 299.55%
• 5 years: -70.43%
• 10 years: -70.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 130